Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | CCR1 | P32246 | 3/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | IL5 | P05113 | 1/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845000 | 0.80 | CYP1A2 (0.61) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL18266965 | 0.78 | CYP1A2 (0.64) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL3065915 | 0.77 | CYP2A6 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL6845001 | 0.77 | CYP2A6 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL28862364 | 0.77 | GRM4 (0.38) | CYP1A2CYP2A6CDK2AKT1 | |
| SCHEMBL2320872 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL1028024 | 0.77 | CYP2A6 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL1563936 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL7990724 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL19001524 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP2A6CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-107072985-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2017-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | CYP1A2 3187/4885CYP2A6 3683/4885CCR1 380/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | CYP1A2 3187/4885CYP2A6 3683/4885CCR1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.